Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
My GOAL is to be a Medical Science Liaison
Summary
In this episode, Jeremy McLemore shares his inspiring journey from pharmaceutical sales to becoming a Medical Science Liaison (MSL). Jeremy discusses his transition into the MSL role, detailing how he discovered the position and pursued it despite setbacks. He reflects on his experiences at Bristol Myers Squibb and AbbVie, highlighting the importance of networking, adaptability, and resilience in career progression. Jeremy also compares sales and MSL roles, offering insights into the unique challenges of each. He concludes with valuable advice for aspiring MSLs and shares his future goals.
Jeremy McLemore, Medical Science Liaison at AbbVie, discusses how his goal was to be an MSL and how he got there.
Jeremy shares….
How he approached his career from PharmD onward
The importance of being flexible and adaptable
Why it makes sense to consider a “starter” Industry role
How sales and field medical affairs differ (and how they are alike)
Medical Science Liaison, pharmaceutical sales, career progression, networking in medical field, MSL career advice
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary